home / stock / snynf / snynf short
Short Information | Sanofi (OTCMKTS:SNYNF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 3,726 |
Total Actual Volume | 614,212 |
Short Trends | |
---|---|
Cover Days | 13 |
Short Days | 6 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 186 |
Average Short Percentage | 27.81% |
Is there a SNYNF Short Squeeze or Breakout about to happen?
See the SNYNF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-01-2024 | $97.76 | $100 | $100 | $96.64 | 535 | 354 | 66.17% |
04-30-2024 | $0 | $95.544 | $0 | $0 | 33 | 2 | 6.06% |
04-29-2024 | $0 | $95.544 | $0 | $0 | 228 | 1 | 0.44% |
04-26-2024 | $0 | $95.544 | $0 | $0 | 28 | 22 | 78.57% |
04-25-2024 | $95.544 | $95.544 | $95.544 | $95.544 | 299 | 60 | 20.07% |
04-24-2024 | $95 | $94 | $95 | $94 | 310 | 110 | 35.48% |
04-23-2024 | $94.25 | $94.25 | $94.25 | $94.25 | 482 | 11 | 2.28% |
04-22-2024 | $0 | $92.7 | $0 | $0 | 77 | 47 | 61.04% |
04-19-2024 | $0 | $92.7 | $0 | $0 | 84 | 13 | 15.48% |
04-18-2024 | $92.7 | $92.7 | $92.7 | $92.7 | 600,729 | 612 | 0.1% |
04-17-2024 | $92.23 | $92.7 | $92.7 | $91.48 | 1,429 | 100 | 7% |
04-16-2024 | $91.336 | $92.116 | $92.116 | $91.336 | 2,296 | 532 | 23.17% |
04-15-2024 | $92.406 | $92.966 | $92.966 | $92.406 | 633 | 49 | 7.74% |
04-11-2024 | $93.4 | $92.9 | $93.4 | $92.9 | 884 | 504 | 57.01% |
04-10-2024 | $94.25 | $94.25 | $94.25 | $94.25 | 1,295 | 20 | 1.54% |
04-09-2024 | $94.26 | $94.26 | $94.26 | $94.26 | 693 | 47 | 6.78% |
04-08-2024 | $94.762 | $94 | $94.762 | $94 | 1,566 | 432 | 27.59% |
04-05-2024 | $94.4 | $92.69 | $94.4 | $92.69 | 239 | 126 | 52.72% |
04-04-2024 | $97.65 | $96.1 | $97.65 | $96.1 | 2,326 | 657 | 28.25% |
04-03-2024 | $0 | $97.65 | $0 | $0 | 46 | 27 | 58.7% |
News, Short Squeeze, Breakout and More Instantly...
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus n...
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composition: renewal of two Directors and appointment of three new Independent Di...
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€...